Join
Live feed
·
PRReleasevia Quantisnow
Aldeyra Therapeutics Inc. logo

Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease

ByQuantisnow·Wall Street's wire, on your screen.
ALDX· Aldeyra Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALDX (Aldeyra Therapeutics Inc.) and more on Quantisnow.